KA/EN
Register
Medicines reference
Search
Search
Active substance

Robenacoxib

Favourites

Coxib NSAID (COX-2 selective). No registration in force in Georgia. Forms: chewable tablet, solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Robenacoxib
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
1–2 mg/kg Dog Musculoskeletal Pain and Inflammation By mouth once daily at the same time
Robexera 20 mg, VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Robexera 20 mg chewable tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
2–4 mg/kg Dog Postoperative Pain
Analgesia
 By mouth 30 minutes before surgery, then once daily for up to 2 days
Robexera 20 mg, VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Robexera 20 mg chewable tablets for dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
2 mg/kg Dog, Cat Postoperative Pain
Analgesia
 Subcutaneous 30 minutes before surgery, then once daily for up to 2 days
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Robexera 20 mg/ml solution for injection for cats and dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
2 mg/kg Dog Postoperative Pain
Analgesia
 Subcutaneous once daily for up to 3 days
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Onsior (robenacoxib) injection for cats and dogs - FDA-approved label
US Food and Drug Administration (DailyMed), 2026
1–2.4 mg/kg Cat Musculoskeletal Pain and Inflammation By mouth once daily at the same time
Robexera 6 mg, VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Robexera 6 mg chewable tablets for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
1–2.4 mg/kg Cat Postoperative Pain
Analgesia
 By mouth 30 minutes before surgery, then once daily for up to 2 days
Robexera 6 mg, VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Robexera 6 mg chewable tablets for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
1 mg/kg Cat Postoperative Pain
Analgesia
 By mouth once daily for up to 3 days
FDA 2026
Official product label (SPC), FDA, US
Approved by the US Food and Drug Administration (FDA) as part of the product's authorisation. It applies to that product as authorised there.
Onsior (robenacoxib) tablets for cats - FDA-approved label
US Food and Drug Administration (DailyMed), 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use robenacoxib in animals with gastrointestinal ulceration. In patients at increased ulcer risk or with previous intolerance to another non-steroidal anti-inflammatory drug, use only under strict veterinary monitoring.
  • Critical
    Do not use robenacoxib in pregnant, lactating, or breeding animals.
  • Critical
    Do not use robenacoxib during lactation.
  • Critical
    known intolerance to NSAIDs
    Sources: FDA
  • Critical (Dog)
    Do not use robenacoxib in dogs with hepatic disease. Stop treatment if liver enzymes rise markedly or if anorexia, apathy, or vomiting develops.
  • Warning
    Robenacoxib carries additional risk in renal impairment. If use cannot be avoided, provide fluid support when indicated and monitor renal function closely; risk may be greater in older cats and with concurrent anaesthetic or sedative drugs.
  • Warning
    Robenacoxib carries additional risk in animals with impaired cardiac function. If use cannot be avoided, assess cardiovascular status and monitor carefully.
  • Warning
    Dehydration, hypovolaemia, and hypotension increase the renal risk of robenacoxib. Correct fluid deficits before treatment and consider parenteral fluids during anaesthesia or surgery because anaesthetics can reduce renal perfusion.
  • Warning
    Age and weight limits for robenacoxib depend on the formulation and market. Do not use a feline tablet in a cat younger than 4 months or weighing less than 2.5 kg, and follow the selected product’s specific minimum-age and minimum-weight restrictions.
  • Warning (Cat)
    Robenacoxib carries additional risk in cats with impaired cardiac, renal, or hepatic function. If use cannot be avoided, monitor the cat carefully.
  • Caution
    Robenacoxib treatment-duration limits differ by product and country. Some labels limit canine treatment to 3 days because serious adverse events, including hepatopathy, occurred with prolonged use; labels permitting longer treatment require scheduled liver-enzyme monitoring. Never give more than one dose per day or combine tablet and injection doses.

Known Drug Interactions

  • Contraindicated Robenacoxib + Dexamethasone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Robenacoxib + Firocoxib
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Robenacoxib + Ketoprofen
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Robenacoxib + Methylprednisolone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Robenacoxib + Prednisolone
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Carprofen + Robenacoxib
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Contraindicated Meloxicam + Robenacoxib
    Do not give robenacoxib together with other non-steroidal anti-inflammatory drugs or glucocorticoids because adverse gastrointestinal and renal effects may increase.
    Recommendation: Do not use these drugs together. Allow a treatment-free interval of at least 24 hours after the previous anti-inflammatory drug, extending it when required by that drug’s pharmacokinetics.
  • Major warning Robenacoxib + Dihydrostreptomycin
    Avoid combining robenacoxib with potentially nephrotoxic medicines because the risk of renal toxicity may increase.
    Recommendation: Avoid concomitant use; if unavoidable, monitor renal function.
  • Minor warning Robenacoxib + Benazepril
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
  • Minor warning Robenacoxib + Enalapril
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
  • Minor warning Robenacoxib + Furosemide
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
  • Minor warning Robenacoxib + Spironolactone
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
  • Minor warning Robenacoxib + Torasemide
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
Latin name
Robenacoxib
Georgian name
რობენაკოქსიბი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 3 forms
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration3

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Robenacoxib 6 mg, Chewable tablet

chewable tablet for cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
Not rateable
No numerical score assigned
vetman assessment

Robenacoxib 6 mg

chewable tablet for cats
Assessed clinical scopeCat · Potential oral treatment of feline acute/chronic musculoskeletal pain or peri-operative orthopaedic pain with this unidentified 6 mg robenacoxib chewable tablet · By mouth
Care settingVeterinary-directed NSAID treatment only after the exact product and label are identified, with hydration, gastrointestinal, renal, hepatic and concurrent-medication risks reviewed.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Unknown · Verified on 22 Oct 2026
Not rateable

A numerical product score cannot responsibly be assigned. Catalogue row 21384 states only robenacoxib, strength, chewable-tablet form and target species; it has no trade name, manufacturer or MA holder, authorisation number, pack, exact label, excipient profile or independent formulation verification. The existing market statuses and dose tables were copied from named Onsior/Robexera products. Those products and clinical trials support robenacoxib's role in the target species, but they cannot establish this unidentified tablet's authorisation, bioequivalence, safety, palatability, subdivision, storage or reliable dose delivery.

Robenacoxib has direct feline acute, chronic and peri-operative evidence and named authorised 6 mg products, but their positive product score cannot be transferred to an unidentified row. Map this record to an exact marketed product before scoring or dosing.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, MA holder, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • Onsior and Robexera are named authorised comparators, not the product identified by this row. Their market statuses and product-specific dose tables must not be transferred.
  • No calculator dose is published for this unidentified presentation. Confirm the actual product and its current label before prescribing; equal active substance and strength do not by themselves prove formulation equivalence.
  • Use the lowest effective NSAID dose for the shortest clinically appropriate duration and reassess response. Stop and investigate if pain control is inadequate rather than extending treatment automatically.
  • Do not combine with another NSAID or a glucocorticoid. Allow an appropriate washout after prior anti-inflammatory treatment, considering the previous product's pharmacokinetics.
  • Do not use with gastrointestinal ulceration, significant dehydration, hypovolaemia or hypotension. Stabilise perfusion first; renal, cardiac or hepatic impairment requires strict case selection and monitoring.
  • Monitor appetite, vomiting, diarrhoea, melaena, lethargy, renal variables and liver enzymes where prolonged treatment is contemplated. Stop and reassess promptly if clinically important abnormalities develop.
  • Do not use during pregnancy or lactation or in breeding animals. Age and weight limits are formulation- and label-specific and cannot be assigned to this unidentified tablet.
  • Review diuretics, ACE inhibitors, anaesthetics and other nephrotoxic or highly protein-bound medicines. Peri-operative patients require attention to renal perfusion and multimodal rescue analgesia.
Assessment sources
  1. Robenacoxib generic identity audit2026
  2. Robexera 6 mg, VMD SPC 20262026
  3. Feline acute MSK trial2010
  4. Feline orthopaedic trial2015
  5. Feline chronic safety2021
  6. FDA 20262026
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Robenacoxib6 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia Unknown EU Not confirmed
Verified on: 22 Oct 2026
 UK Not confirmed
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dose is published for this unidentified exact product. Robexera 6 mg and Onsior are authorised comparators, not the product identified by this row; confirm the trade name, manufacturer and label before using a product-specific regimen.

Robenacoxib 20 mg, Chewable tablet

chewable tablet for dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Not rateable
No numerical score assigned
vetman assessment

Robenacoxib 20 mg

chewable tablet for dogs
Assessed clinical scopeDog · Potential oral treatment of canine chronic osteoarthritis or short peri-operative soft-tissue pain with this unidentified 20 mg robenacoxib chewable tablet · By mouth
Care settingVeterinary-directed NSAID treatment only after the exact product and label are identified, with hydration, gastrointestinal, renal, hepatic and concurrent-medication risks reviewed.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Unknown · Verified on 22 Oct 2026
Not rateable

A numerical product score cannot responsibly be assigned. Catalogue row 21383 states only robenacoxib, strength, chewable-tablet form and target species; it has no trade name, manufacturer or MA holder, authorisation number, pack, exact label, excipient profile or independent formulation verification. The existing market statuses and dose tables were copied from named Onsior/Robexera products. Those products and clinical trials support robenacoxib's role in the target species, but they cannot establish this unidentified tablet's authorisation, bioequivalence, safety, palatability, subdivision, storage or reliable dose delivery.

Robenacoxib has direct canine osteoarthritis evidence and named authorised 20 mg products, but their positive product score cannot be transferred to an unidentified row. Map this record to an exact marketed product before scoring or dosing.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, MA holder, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • Onsior and Robexera are named authorised comparators, not the product identified by this row. Their market statuses and product-specific dose tables must not be transferred.
  • No calculator dose is published for this unidentified presentation. Confirm the actual product and its current label before prescribing; equal active substance and strength do not by themselves prove formulation equivalence.
  • Use the lowest effective NSAID dose for the shortest clinically appropriate duration and reassess response. Stop and investigate if pain control is inadequate rather than extending treatment automatically.
  • Do not combine with another NSAID or a glucocorticoid. Allow an appropriate washout after prior anti-inflammatory treatment, considering the previous product's pharmacokinetics.
  • Do not use with gastrointestinal ulceration, significant dehydration, hypovolaemia or hypotension. Stabilise perfusion first; renal, cardiac or hepatic impairment requires strict case selection and monitoring.
  • Monitor appetite, vomiting, diarrhoea, melaena, lethargy, renal variables and liver enzymes where prolonged treatment is contemplated. Stop and reassess promptly if clinically important abnormalities develop.
  • Do not use during pregnancy or lactation or in breeding animals. Age and weight limits are formulation- and label-specific and cannot be assigned to this unidentified tablet.
  • Review diuretics, ACE inhibitors, anaesthetics and other nephrotoxic or highly protein-bound medicines. Peri-operative patients require attention to renal perfusion and multimodal rescue analgesia.
Assessment sources
  1. Robenacoxib generic identity audit2026
  2. Robexera 20 mg, VMD SPC 20262026
  3. Canine OA trial2012
  4. Canine OA 12-week trial2012
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Robenacoxib20 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia Unknown EU Not confirmed
Verified on: 22 Oct 2026
 UK Not confirmed
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dose is published for this unidentified exact product. Robexera 20 mg and Onsior are authorised comparators, not the product identified by this row; confirm the trade name, manufacturer and label before using a product-specific regimen.

Robenacoxib 20 mg/ml, Solution

solution for injection for cats and dogs
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential SC peri-operative control of canine pain and inflammation with this unidentified 20 mg/ml robenacoxib injection
Not rateable
No numerical score assigned
vetman assessment

Robenacoxib 20 mg/ml

solution for injection for cats and dogs
Assessed clinical scopeDog · Potential SC peri-operative control of canine pain and inflammation with this unidentified 20 mg/ml robenacoxib injection · Subcutaneous
Care settingVeterinary peri-operative care only after the exact sterile product and current label are identified, with multimodal analgesia and renal-perfusion monitoring.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Unknown · Verified on 22 Oct 2026
Not rateable

A numerical product score cannot responsibly be assigned. Catalogue row 21385 states only robenacoxib, 20 mg/ml strength, injectable solution, SC route and dog/cat target species; it has no trade name, manufacturer or MA holder, authorisation number, pack, exact label, excipient profile, storage or independent formulation verification. Existing market statuses and the 0.1 ml/kg dose were transferred from named Onsior/Robexera products. Those products support the clinical role of robenacoxib injection, but cannot establish this unidentified presentation's authorisation, bioequivalence, sterility, safety, handling or reliable dose delivery in dog.

Named authorised robenacoxib injections have direct canine peri-operative evidence, but their positive product score cannot be transferred to an unidentified row. Map this record to the exact administered product before scoring or dosing.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, MA holder, authorisation, bioequivalence, sterility, excipients, vial size or quality from the generic catalogue name.
  • Onsior and Robexera are named authorised comparators, not the product identified by this row. Their market status, formulation-specific evidence and handling instructions must not be transferred.
  • No calculator dose is published for this unidentified injection. Confirm the actual vial and current label before prescribing; equal active substance, strength and route do not by themselves prove formulation equivalence.
  • This is peri-operative anti-inflammatory analgesia, not complete stand-alone surgical analgesia. Use a multimodal plan, formal pain assessment and timely rescue analgesia.
  • Do not combine with another NSAID or a glucocorticoid. Allow an appropriate washout after previous anti-inflammatory treatment, considering the prior product's pharmacokinetics.
  • Do not use with gastrointestinal ulceration or unstable dehydration, hypovolaemia or hypotension. Stabilise perfusion first; renal, cardiac or hepatic impairment requires strict case selection and monitoring.
  • Monitor appetite, vomiting, diarrhoea, melaena, injection-site reaction, renal variables and clinically indicated liver values. Stop and reassess promptly if important abnormalities develop.
  • Pregnancy, lactation, breeding, minimum-age and minimum-weight restrictions are product-label specific and cannot be assigned safely to this unidentified presentation.
  • Review diuretics, ACE inhibitors, anaesthetics and other nephrotoxic or highly protein-bound medicines. Anaesthesia can reduce renal perfusion, so plan fluids and monitoring for the individual patient.
  • Storage temperature, time after first puncture, maximum vial punctures, mixing restrictions and sodium-metabisulfite content differ by exact product and must be read from the administered vial's label.
Assessment sources
  1. Robenacoxib GE comparator audit2026
  2. FDA 20262026
  3. Onsior injection UPD2026
  4. VMD SPC 20252025
  5. Robexera injection VMD record2026
  6. Robexera injection PAR2026
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential SC peri-operative control of feline pain and inflammation with this unidentified 20 mg/ml robenacoxib injection
Not rateable
No numerical score assigned
vetman assessment

Robenacoxib 20 mg/ml

solution for injection for cats and dogs
Assessed clinical scopeCat · Potential SC peri-operative control of feline pain and inflammation with this unidentified 20 mg/ml robenacoxib injection · Subcutaneous
Care settingVeterinary peri-operative care only after the exact sterile product and current label are identified, with multimodal analgesia and renal-perfusion monitoring.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Unknown · Verified on 22 Oct 2026
Not rateable

A numerical product score cannot responsibly be assigned. Catalogue row 21385 states only robenacoxib, 20 mg/ml strength, injectable solution, SC route and dog/cat target species; it has no trade name, manufacturer or MA holder, authorisation number, pack, exact label, excipient profile, storage or independent formulation verification. Existing market statuses and the 0.1 ml/kg dose were transferred from named Onsior/Robexera products. Those products support the clinical role of robenacoxib injection, but cannot establish this unidentified presentation's authorisation, bioequivalence, sterility, safety, handling or reliable dose delivery in cat.

Named authorised robenacoxib injections have direct feline peri-operative evidence, but their positive product score cannot be transferred to an unidentified row. Map this record to the exact administered product before scoring or dosing.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, MA holder, authorisation, bioequivalence, sterility, excipients, vial size or quality from the generic catalogue name.
  • Onsior and Robexera are named authorised comparators, not the product identified by this row. Their market status, formulation-specific evidence and handling instructions must not be transferred.
  • No calculator dose is published for this unidentified injection. Confirm the actual vial and current label before prescribing; equal active substance, strength and route do not by themselves prove formulation equivalence.
  • This is peri-operative anti-inflammatory analgesia, not complete stand-alone surgical analgesia. Use a multimodal plan, formal pain assessment and timely rescue analgesia.
  • Do not combine with another NSAID or a glucocorticoid. Allow an appropriate washout after previous anti-inflammatory treatment, considering the prior product's pharmacokinetics.
  • Do not use with gastrointestinal ulceration or unstable dehydration, hypovolaemia or hypotension. Stabilise perfusion first; renal, cardiac or hepatic impairment requires strict case selection and monitoring.
  • Monitor appetite, vomiting, diarrhoea, melaena, injection-site reaction, renal variables and clinically indicated liver values. Stop and reassess promptly if important abnormalities develop.
  • Pregnancy, lactation, breeding, minimum-age and minimum-weight restrictions are product-label specific and cannot be assigned safely to this unidentified presentation.
  • Review diuretics, ACE inhibitors, anaesthetics and other nephrotoxic or highly protein-bound medicines. Anaesthesia can reduce renal perfusion, so plan fluids and monitoring for the individual patient.
  • Storage temperature, time after first puncture, maximum vial punctures, mixing restrictions and sodium-metabisulfite content differ by exact product and must be read from the administered vial's label.
Assessment sources
  1. Robenacoxib GE comparator audit2026
  2. FDA 20262026
  3. Onsior injection UPD2026
  4. VMD SPC 20252025
  5. Robexera injection VMD record2026
  6. Robexera injection PAR2026
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Robenacoxib20 mg/ml
Formulation Type
Solution
Administration route
Subcutaneous
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia Unknown EU Not confirmed
Verified on: 22 Oct 2026
 UK Not confirmed
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dose is published for this unidentified exact product. Named Onsior and Robexera 20 mg/ml injections are authorised comparators, not the product identified by this row; confirm the trade name, manufacturer, authorisation and current label before using a product-specific regimen.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗